Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
DOI
PMC
 |
|
|
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
Adipokines as clinically relevant therapeutic targets in obesity.
Biomedicines 11:26 (2023)
Adipokines provide an outstanding role in the comprehensive etiology of obesity and may link adipose tissue dysfunction to further metabolic and cardiovascular complications. Although several adipokines have been identified in terms of their physiological roles, many regulatory circuits remain unclear and translation from experimental studies to clinical applications has yet to occur. Nevertheless, due to their complex metabolic properties, adipokines offer immense potential for their use both as obesity-associated biomarkers and as relevant treatment strategies for overweight, obesity and metabolic comorbidities. To provide an overview of the current clinical use of adipokines, this review summarizes clinical studies investigating the potential of various adipokines with respect to diagnostic and therapeutic treatment strategies for obesity and linked metabolic disorders. Furthermore, an overview of adipokines, for which a potential for clinical use has been demonstrated in experimental studies to date, will be presented. In particular, promising data revealed that fibroblast growth factor (FGF)-19, FGF-21 and leptin offer great potential for future clinical application in the treatment of obesity and related comorbidities. Based on data from animal studies or other clinical applications in addition to obesity, adipokines including adiponectin, vaspin, resistin, chemerin, visfatin, bone morphogenetic protein 7 (BMP-7) and tumor necrosis factor alpha (TNF-α) provide potential for human clinical application.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Adipokines ; Biomarker ; Obesity ; Therapeutic Strategy; Tumor-necrosis-factor; Reduces Food-intake; Congenital Leptin Deficiency; Bone Morphogenetic Protein-7; Adipose-tissue Expression; Insulin-resistance; Metabolic Syndrome; Factor-alpha; Body-weight; Circulating Fgf21
ISSN (print) / ISBN
2227-9059
e-ISSN
2227-9059
Journal
Biomedicines
Quellenangaben
Volume: 11,
Issue: 5,
Article Number: 26
Publisher
MDPI
Publishing Place
Basel, Switzerland
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
Grants
Deutsche Forschungsgemeinschaft (DFG, German Research foundation)